Skip to content

    Pseudoeph-Triprolidine-Cod Syrup

    precautions

    What should I know regarding pregnancy, nursing and administering Pseudoeph-Triprolidine-Cod Syrup to children or the elderly?

    If you are:

    Pregnant:

    Only When Necessary: NEONATAL WITHDRAWAL/RESP.DEPRESS. W/CHRONIC OR HIGH DOSE; SMALL TERATOGENIC RISK

    Only When Necessary: FDA C W/COMBO PROD; POSS RISK OF GASTROSCHISIS/SIA WITH 1ST TRIMESTER EXPOSURE

    Only When Necessary: FDA CATEGORY C IN COMBINATION PRODUCT

    Nursing:

    Absolute Contraindication: CNS/RESPIRATORY DEPRESSION,APNEA POSSIBLE;CAUTION W/ FAST CYP2D6 METABOLIZER

    Precaution: MAY DECREASE MILK SUPPLY, AND CAUSE IRRITABILITY

    An adult over 60:

    management or monitoring precaution: Cardiovascular-Elderly are more sensitive to tachycardia and hypertensive effects. May exacerbate symptomatic coronary insufficiency. Genitourinary-May cause urinary retention. Neuro/Psych-May worsen cognitive impairment in some elderly with dementia. Insomnia risk.

    management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.

    management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.

    Giving pseudoeph-triprolidine-cod Syrup to a child under 12:

    Contraindication: Do not use in pediatrics <6 years of age unless clinician consultation.

    Severe Precaution: Contraindicated for pain management post-surgical tonsillectomy and or adenoidectomy. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizer patients post tonsillectomy or adenoidectomy. Avoid in patient with obesity, obstructive sleep apnea, asthma or other underlying breathing problem.

    Contraindication: Increased risk of CNS and respiratory depression. Contraindicated age < 12 years. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy. Risk increases with obesity, asthma, obstructive sleep apnea or other underlying lung or breathing problem.

    Contraindication: High risk of adverse CNS effects. Not recommended for use age < 6 years.

    Contraindication: Use not recommended age <4 months. CNS excitation and seizure risk in newborns.

    Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

    CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

    More about Drugs and Medications

    URAC Seal TRUSTe Privacy Certification TAG Registered Seal HONcode Seal AdChoices